Latest filing published 02 Oct 2023 for Transcode Therapeutics, Inc., €24k.
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Thomas A. Fitzgerald: trading record in brief
Thomas A. Fitzgerald (finance chief) discloses dealings in Transcode Therapeutics, Inc. to SEC (Form 4). The record holds 2 filings, for trades running from 16 June 2022 to 28 September 2023.
No open-market sale appears; the market trades are 2 purchases worth €38k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2023, the count stands at 1 purchase and no sales.
The latest filing, published on 2 October 2023, reports an open-market purchase of €24k in Transcode Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Thomas A. Fitzgerald
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 49,350 shares@ US$0.5162.3% of flowCommon StockSEC:0001104659-23-105925:0Canonical exit: 27 Dec 2023 (T+90)
- 12,000 shares@ US$1.2737.7% of flowCommon StockSEC:0001104659-22-072369:0Canonical exit: 14 Sept 2022 (T+90)
2 of 2 declarations